Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
Sign Up to like & getrecommendations! Published in 2020 at "OncoTargets and therapy"
DOI: 10.2147/ott.s273866
Abstract: Background Post hoc analysis of the LUX-Lung 3 and 6 (LL3/6) Phase III trials showed that tolerability-guided dose-adjustments of afatinib reduced treatment-related adverse events (TRAEs) without affecting progression-free survival (PFS) in patients with epidermal growth… read more here.
Keywords: lux lung; dose reduction; dose adjustments; tolerability guided ... See more keywords